Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01922193
Recruitment Status : Completed
First Posted : August 14, 2013
Last Update Posted : June 16, 2015
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals

Brief Summary:
Evaluate the efficacy and safety of of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program.

Condition or disease Intervention/treatment Phase
Infertility Drug: Highly Purified Urofollitropin Drug: Recombinant Human Follitropin Alfa Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 263 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Controlled Ovarian Stimulation in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
Study Start Date : October 2013
Actual Primary Completion Date : February 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Test Group Drug: Highly Purified Urofollitropin
for injection
Other Name: Bravelle®

Active Comparator: Control Group Drug: Recombinant Human Follitropin Alfa
for injection
Other Name: Gonal-F®




Primary Outcome Measures :
  1. The number of retrieved oocytes per cycle [ Time Frame: About 36 hours post hCG (human chorionic gonadotrophin) ]

Secondary Outcome Measures :
  1. The follicles development [ Time Frame: At day 5 of FSH preparation stimulation and the day of hCG administration ]
  2. The fertilization rate [ Time Frame: 20h (± 1h) after insemination ]
  3. Implantation rate [ Time Frame: 5-6 weeks post embryo transfer ]
  4. Cycle cancellation rate [ Time Frame: 36 hours post hCG ]
  5. The positive serum β-hCG/hCG rate [ Time Frame: 13-15 days after embryo transfer ]
  6. The clinical pregnancy rate [ Time Frame: 5-6 weeks after embryo transfer ]
    Regardless of fetal heart beat

  7. The clinical pregnancy rate [ Time Frame: 5-6 weeks after embryo transfer ]
    With fetal heart beat

  8. The ongoing pregnancy rate [ Time Frame: 10-11 weeks after embryo transfer ]
  9. Total gonadotropin dose administered and the duration of gonadotropin treatment [ Time Frame: Up to day 16 (in the stimulation period) ]
  10. Serum E2 (Estradiol) concentrations [ Time Frame: On the day of hCG administration ]
  11. Frequency and severity of adverse events [ Time Frame: Expected maximum of 7 months ]
  12. Frequency and severity of injection site reactions [ Time Frame: Day 1 up to day 16 of the controlled ovarian stimulation period ]
    Injection site reactions (in terms of "redness", "pain", "itching", "swelling" and "bruising")



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent form, prior to screening evaluations
  • In good physical and mental health
  • Chinese Females between the ages of 20-39 years.
  • Body mass index (BMI) is ≥ 18.5 and < 28 kg/m2
  • Female diagnosed for at least one year (i.e., before screening) with tubal infertility, unexplained infertility, male factor infertility
  • Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory
  • Documented evidence of at least one of the following within ninety (90) days prior to down regulation treatment:

    • mid-luteal phase serum progesterone level > 5ng/mL, or
    • late luteal phase endometrial biopsy with < 3 days lag, or
    • biphasic basal body temperature chart, or
    • mid-cycle urinary LH (Luteinizing hormone)surge
  • Early follicular phase (day 2-3), serum levels of FSH within limits (1-12IU/L)(results obtained within 90 days prior to down regulation treatment)
  • LH, PRL (prolactin), E2 (Estradiol), P (progesterone), total testosterone levels within normal range for the clinical laboratory or considered not clinically significant by the investigator (results obtained within 90 days prior to down regulation treatment)
  • TSH (thyrotropin) levels within normal limits for the clinical laboratory or considered not clinically significant by the investigator, or secondary to exogenous thyroid medication (results obtained within 90 days prior to down regulation treatment)
  • Negative serum Human Immunodeficiency Virus (HIV) antibody, and TPPA (Treponema Pallidum antibodies)/ RPR (Rapid Plasma Reagin) tests (results obtained within 90 days prior to down regulation treatment)
  • Early follicular phase total antral follicle (diameter 2-10 mm) count ≥ 6 and ≤ 25 for both ovaries combined (results obtained within 3 months prior to down regulation treatment)
  • Transvaginal ultrasound documenting presence and adequate visualisation of both ovaries, uterus and adnexa without evidence of significant abnormality (e.g.no endometrioma greater than 3 cm, no ovarian cysts > 35 mm or enlarged ovaries which would contraindicate the use of down regulation treatment, no hydrosalpinx) within ninety (90) days prior to down regulation treatment
  • Hysterosalpingography, hysteroscopy, saline infusion sonography or transvaginal ultrasound documenting a uterus consistent with expected normal function (e.g.no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are incompatible with pregnancy) within 1 year prior to down regulation treatment. This also includes women who have been diagnosed with any of the above medical conditions but have had them surgically corrected.
  • A minimum of one cycle without treatment with fertility modifiers (e.g., oral contraceptives) during the last menstrual cycle before down regulation treatment
  • Willing to accept a maximum of two embryos transferred in the fresh cycle
  • Willing to use an adequate barrier method of contraception or refrain from intercourse from 2 weeks before start of down regulation and throughout the down regulation period

Exclusion Criteria:

  • Any pregnancy within last three (3) months prior to screening
  • Known past or current thrombophlebitis or thromboembolism including venous thrombosis disease and active or recent arterial thrombosis disease
  • Three or more controlled ovarian stimulation cycles for IVF/ICSI (In vitro fertilization/Intracytoplasmic sperm injection) prior to screening
  • Previous IVF or ART failure related to a sperm/fertilization problem which resulted in unsuccessful fertilization and no related medical conditions improved
  • Known history of poor ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI
  • Known history of excessive ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI
  • Known severe OHSS (Ovarian hyperstimulating syndrome) in a previous controlled ovarian stimulation cycle.
  • Known history of polycystic ovary disease (PCOD) associated with anovulation
  • Known endometriosis
  • Known abnormal results of cervical examination of clinical significance obtained within 1 year prior to screening
  • Abnormal vaginal bleeding of undetermined origin
  • Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus
  • Known current active pelvic inflammatory disease
  • Known history of recurrent miscarriage
  • Known malformations of the sexual organs incompatible with pregnancy
  • According to the judgment of the investigator, abnormal laboratory value of renal or hepatic function is clinically significant
  • Known current (3 months prior to screening) or past (1 year prior to screening) abuse of alcohol or drugs, and/or current or past smoking habit of more than 10 cigarettes per day
  • Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the trial with the exception of controlled thyroid function disease
  • Known history of chemotherapy (except for gestational conditions) or radiotherapy
  • According to the judgment of the investigator, abnormal laboratory value is clinically relevant
  • Use of any non-registered investigational drugs during 3 months before screening or previous participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922193


Locations
Layout table for location information
China, Beijing
Chinese PLA General Hospital
Beijing, Beijing, China
Peking Union Medical College Hospital
Beijing, Beijing, China
Peking University First Hospital
Beijing, Beijing, China
Peking University People's Hospital
Beijing, Beijing, China
China, Guangdong
Sun Yat-sen Memorial Hospital Sun Yat-sen University
Guangzhou, Guangdong, China
The third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
China, Hubei
Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China
China, Jiangsu
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
China, Liaoning
ShengJing Hospital of China Medical University
Shenyang, Liaoning, China
China, Sichuan
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
China, Tianjin
Tianjin Medical University General Hospital
Tianjin, Tianjin, China
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Development Support Ferring Pharmaceuticals

Layout table for additonal information
Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01922193     History of Changes
Other Study ID Numbers: 000089
First Posted: August 14, 2013    Key Record Dates
Last Update Posted: June 16, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Infertility
Genital Diseases, Male
Genital Diseases, Female
Follicle Stimulating Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs